Abstract 【Objective】To investigate the changes of serum miR-152 and mir-32 levels in patients with prostate cancer and their relationship with pathological stage and Gleason score. 【Methods】From January 2016 to may 2018, patients with prostate cancer (observation group,n=80) and patients with prostate hyperplasia (control group,n=80) were selected. The serum levels of miR-152 and miR-32 were detected and compared between the two groups, and stratified analysis was performed according to the pathological stage, PSA and Gleason score. Hierarchical analysis was performed according to pathological staging, PSA and Gleason scores. 【Results】 The level of serum miR-32 in the observation group was significantly higher than that in the control group (P<0.05); the level of serum miR-152 in the observation group was significantly lower than that in the control group (P<0.05). There was significant difference in serum miR-152 level between patients with prostate cancer of different pathological stages and lymph node metastasis (P<0.05); there was no significant difference in serum miR-152 level of prostate cancer patients with different Gleason scores (P>0.05). There were statistically significant differences in serum mir-32 levels among prostate cancer patients with different pathological stages, lymph node metastasis and Gleason score (P<0.05).【Conclusion】 The serum miR-152 level of prostate cancer patients decreased significantly, the miR-32 level increased significantly, and both are closely related to the clinicopathological characteristics of the patients.
2020, Vol. 37 
